Oxygen-Substituted Propionic Acid Derivatives for Cathepsin A Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cathepsin A inhibitors are limited in their ability to effectively treat a range of diseases including atherosclerosis, heart failure, renal diseases, and inflammatory conditions, with a need for more compounds that can inhibit cathepsin A to modulate bradykinin levels and provide therapeutic benefits.
Innovation Solution
Development of oxygen-substituted 3-heteroaroylamino-propionic acid derivatives that specifically inhibit cathepsin A, offering a new class of compounds capable of treating various diseases by modulating the enzyme's activity and bradykinin levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing cathepsin A inhibitors are used, then some therapeutic effect is achieved, but the ability to effectively treat a range of diseases including atherosclerosis, heart failure, renal diseases, and inflammatory conditions is limited
Solution Approach 1:
The patent applies parameter changes by systematically varying molecular parameters of cathepsin A inhibitors, including introducing oxygen-substituted heteroaroyl groups at different positions, modifying alkyl chain lengths, and changing substituent types. These parameter variations create a series of compounds with optimized catalytic inhibition activity while maintaining structural diversity for broad disease applicability
Solution Approach 2:
The patent achieves universality by designing a core propionic acid derivative structure with heteroaroyl substitution that can effectively inhibit cathepsin A across multiple disease contexts. The compounds demonstrate multi-functionality by treating cardiovascular diseases (atherosclerosis, heart failure), renal diseases, inflammatory conditions, and other cathepsin A-related disorders through a single molecular scaffold
2Reliability
If cathepsin A inhibition is increased to modulate bradykinin levels, then therapeutic benefits for cardiovascular and renal diseases are improved, but the complexity of compound structure increases
Solution Approach 1:
The patent applies segmentation by dividing the inhibitor molecule into distinct functional segments: a core propionic acid derivative backbone, heteroaroyl substitution groups (pyridyl, pyrimidyl, triazyl rings), oxygen-substituted side chains, and alkyl modifications. This segmented approach allows systematic optimization of each segment's contribution to cathepsin A inhibition while maintaining overall structural manageability
Solution Approach 2:
The patent implements local quality by introducing specific oxygen-substituted heteroaroyl groups at particular positions on the propionic acid core structure. Different positions and types of heteroaroyl substitutions (e.g., 3-pyridyl vs. 2-pyrimidyl) provide localized functional enhancements that optimize bradykinin modulation and cathepsin A inhibition without requiring complete structural redesign
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively inhibit cathepsin A, providing therapeutic benefits for cardiovascular, renal, and inflammatory diseases by regulating bradykinin levels and offering potential for treating conditions such as hypertension, heart failure, and renal fibrosis.
Implementation Method 1
They are inhibitors of the protease cathepsin A
Data Source
AI summary
The present invention relates to compounds of the formula (I), wherein X, R, R1, R2, D, E1, E2, E3, E4, G1, G2, G3 and G4 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the treatment of diseases such as atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula (I), their use and pharmaceutical compositions comprising them.